The Goldman Sachs Group set a GBX 6,800 ($88.84) target price on AstraZeneca (LON:AZN) in a report released on Tuesday morning, Borsen Zeitung reports. The firm currently has a sell rating on the biopharmaceutical company’s stock.
AZN has been the subject of a number of other research reports. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell restated a buy rating and set a £100 ($130.65) target price on shares of AstraZeneca in a research report on Thursday, April 8th. Deutsche Bank Aktiengesellschaft set a £102 ($133.26) target price on shares of AstraZeneca and gave the stock a buy rating in a research report on Tuesday. Kepler Capital Markets set a GBX 9,200 ($120.20) target price on shares of AstraZeneca and gave the stock a buy rating in a research report on Monday, May 3rd. Berenberg Bank restated a buy rating on shares of AstraZeneca in a research report on Friday, April 16th. Finally, DZ Bank restated a sell rating on shares of AstraZeneca in a research report on Monday, May 3rd. Four analysts have rated the stock with a sell rating and fourteen have given a buy rating to the stock. AstraZeneca has an average rating of Buy and a consensus target price of GBX 8,886.25 ($116.10).
Shares of LON AZN opened at GBX 7,864 ($102.74) on Tuesday. The company has a quick ratio of 0.67, a current ratio of 0.87 and a debt-to-equity ratio of 155.65. AstraZeneca has a 52 week low of GBX 71.46 ($0.93) and a 52 week high of £101.20 ($132.22). The firm has a 50-day moving average price of GBX 7,446.60 and a 200 day moving average price of GBX 7,553.47. The stock has a market capitalization of £103.23 billion and a price-to-earnings ratio of 36.47.
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
Featured Article: Shanghai Stock Exchange Composite Index
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.